- Home
- TDC vs XENE Comparison
TDC vs XENE Comparison
Compare TDC & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TDC | XENE |
|---|---|---|
| Founded | 1979 | 1996 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 3.2B |
| IPO Year | 2007 | 2014 |
Fundamental Metrics
Financial Performance| Metric | TDC | XENE |
|---|---|---|
| Price | $25.92 | $59.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 12 |
| Target Price | $35.00 | ★ $67.17 |
| AVG Volume (30 Days) | ★ 1.7M | 1.1M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 16.38 | N/A |
| EPS | ★ 1.35 | N/A |
| Revenue | ★ $2,156,000,000.00 | $311,000.00 |
| Revenue This Year | $0.30 | N/A |
| Revenue Next Year | $1.38 | $2,436.26 |
| P/E Ratio | $19.29 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $19.71 | $28.19 |
| 52 Week High | $41.78 | $62.91 |
Technical Indicators
Market Signals| Indicator | TDC | XENE |
|---|---|---|
| Relative Strength Index (RSI) | 46.04 | 67.24 |
| Support Level | $25.90 | $39.93 |
| Resistance Level | $32.03 | $59.44 |
| Average True Range (ATR) | 1.14 | 1.92 |
| MACD | 0.15 | -0.12 |
| Stochastic Oscillator | 61.46 | 88.93 |
Price Performance
Historical ComparisonAbout TDC Teradata Corporation
Teradata Corp focused on helping organizations improve business performance, enrich customer experiences, and integrate data across the enterprise. The company's platform provides companies with Harmonized Data: Trusted AI: Teradata VantageCloud: Teradata VantageCore: ClearScape Analytics: and Query Grid. The company generates majority of revenue from the United States.
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.